GenomOncology, CompanionDx to Partner on NGS-based Cancer Panels | GenomeWeb

NEW YORK (GenomeWeb News) – CompanionDx and GenomOncology will develop a series of next-generation sequencing-based assays for cancer, the companies said today.

CompanionDx will use GenomOncology's GO Clinical Workbench software to develop a clinical report from the raw sequencing data.

The GO Clinical Workbench analysis is fully traceable and includes a decision support tool for the interpretation of somatic mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.